Breaking Down ThermoGenesis’ Recent Patent for Its Breakthrough Serological Test Reader Technology

ThermoGenesis recently announced that the United States Patent and Trademark Office (USPTO) has accepted a patent application for the company’s new breakthrough lateral flow immunoassay test reader technology.


What is an Antibody Lateral Flow Immunoassay Test?

An antibody lateral flow immunoassay (LFIA) test is a simple diagnostic device used to confirm the presence or absence of specific antibodies in a small blood sample. LFIAs are the fastest, least expensive, and most readily mass-produced bodily fluid test currently on the market. They have been essential in the fight against the current COVID-19 pandemic by providing speedy results (between 10-15 minutes), while being cost effective to produce and distribute worldwide. 


The ThermoGenesis Antibody Lateral Flow Immunoassay Test Reader 

The ThermoGenesis Lateral Flow Immunoassay Test Reader is a handheld, rechargeable, fieldable device designed to improve upon the conventional LFIA test. By taking the standard LFIA test and incorporating sophisticated data reporting and cloud-based software, medically trained professionals will now be able to record and share antibody test results more effectively and accurately than ever before. 


How Will the ThermoGenesis Antibody Lateral Flow Immunoassay Test Reader Help with COVID-19?

The benefits of the ThermoGenesis LFIA Test Reader are two-fold.

First, as the world approaches a commercially available coronavirus vaccine, there will initially be more demand than supply. The advancement in LFIA technology will help facilitate a more efficient utilization of America’s COVID-19 vaccine stocks by helping identify which members of the population already possess the coronavirus antibodies (seropositive) and which don’t (seronegative). Individuals who are tested and found to be seronegative are at greater risk and will therefore be given higher priority to receive the vaccine first.   

Second, the reader will allow researchers to track the vaccine response over time. Once a vaccine is administered, the test reader will then help determine how long the body will be responsive to that vaccine. While some vaccines last for life, others require booster immunizations every year, every five years or every decade. Effective antibody tracking with the ThermoGenesis Reader will help determine exactly how long this COVID-19 vaccine will be effective and how often, if at all, it will need to be readministered. 

Once the ThermoGenesis Reader is available, it will play an important role in creating an efficient immunization strategy that will help lead to the end of this current global pandemic. 


ThermoGenesis Here to Help

ThermoGenesis Holdings, Inc. (formerly Cesca Therapeutics Inc.), is a pioneer and market leader in the development and commercialization of automated cell processing technologies for the cell and gene therapy fields. We market a full suite of solutions for automated clinical biobanking, COVID-19 antibody testing, point-of-care applications and large scale cell processing and manufacturing with a special emphasis on the emerging CAR T immunotherapy market. We are committed to making the world a healthier place by creating innovative health solutions for everyone. 

If you’re a healthcare professional looking for more information on how to buy our COVID-19 IgG/IgM antibody testing kit, COVID-19 Coronavirus Real Time PCR Kit or want to inquire about our testing services visit our website and request a quote today

How may we help?